The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist darifenacin, oral hyoscine hydrobromide and placebo on motion sickness induced by cross-coupled stimulation.
Introduction
Hyoscine hydrobromide, which is effective in the prophylaxis of motion sickness [1] shows similar binding affinities to all of the five known muscarinic acetylcholine receptor subtypes [2] . However, hyoscine hydrobromide can produce a number of unwanted side effects including blurred vision, drowsiness and impaired psychomotor performance [3] [4] [5] . The development of selective muscarinic receptor antagonists with central actions leads to the possibility of enabling motion sickness protection with reduced side effects, provided that there is a functional separation between the roles of central muscarinic receptor subtypes. Darifenacin is a selective muscarinic M3 receptor antagonist with good selectivity over atrial M2 and neuronal M1 receptors. Animal studies confirm central nervous system (CNS) penetration by darifenacin following oral administration [6] .
Darifenacin is approved for the treatment of urge urinary incontinence (UUI). Short-term studies have shown that commonly used non-selective anti-muscarinic drugs such as oxybutynin, have a detrimental effect on cognitive function [7] .
We have compared the effects on motion sickness elicited by cross-coupled stimulation of darifenacin and of hyoscine hydrobromide. In addition, the effects on sweating measured by skin conductance (SC) and on a variety of aspects of psychomotor and cognitive function were evaluated.
Methods

Study design
This was a randomized, placebo-controlled, double-blind, four-way crossover study. Over four study sessions the subjects were dosed with single oral doses of darifenacin 10 mg, darifenacin 20 mg, hyoscine hydrobromide 0.6 mg or placebo. The order of administration of the four treatments was counterbalanced between subjects using a Latin Square design.
Each study session had two stages. In the first, the motion challenge described below was conducted 90 min after treatment administration. SC was also measured. In order to avoid any problems of timings or effects and interactions of cognitive performance with motion sickness, the various CNS assessments including self-ratings and the performance of cognitive tests were conducted on a separate occasion at least 48 h following the motion sickness study. The same dosing condition was administered.
On the treatment days the drugs were administered with 200 ml of water. Subjects were not required to fast overnight prior to study drug administration; however, no heavy meals were allowed the night before and no food consumption was allowed 1 h before drug administration. Subjects were required to not consume any alcohol for 24 h, and to not smoke for 1 h before treatment.
The darifenacin used in the study was an immediate release formulation administered orally in a capsule. For the purposes of this study two doses were prepared. Capsules contained either 10 mg or 20 mg of darifenacin. Matching placebo and hyoscine hydrobromide 0.6 mg capsules were also provided by Pfizer (Tadworth, UK).
The washout period between treatments was 48 h and deemed acceptable, given that the terminal half-life (t 1/2 ) of darifenacin and hyoscine hydrobromide was 3.5-4.5 h and 1-4.5 h, respectively.
The doses of these drugs were determined on the basis of previously published data. Hyoscine hydrobromide 0.6 mg is the standard dose for these types of clinical studies and the pharmacokinetic profile of this dose has been well studied [8] .
The immediate-release (IR) formulation of darifenacin (10 mg and 20 mg) showed similar effects on the bladder as the IR oxybutynin [9], albeit producing less dry mouth. The pharmacokinetic properties of the IR and controlledrelease (CR) darifenacin were similar with respect to t max , albeit IR darifenacin has an increased peak-to-trough ratio compared to CR [9] [10] [11] [12] .
Subjects
Subjects were 16 healthy male volunteers (mean age 26.47 years; SD 7.94, range 17-43 years) with intact vestibular function and not currently on other medications. Prior to any study-related procedures taking place, the subjects were fully informed of the procedures involved in this study and the risks of taking these drugs and their informed consent was obtained. Subjects were free to withdraw from the study any time. This study was approved by the Kent and Canterbury Hospital Ethics committee. During the consent and screening process the subjects' eligibility, medical history, medication use and fitness was thoroughly assessed by the investigators. Subjects were given sufficient time to read the 'Information for Volunteers' document and make an informed decision. All information provided by subjects was treated with confidentiality and integrity. All trial-related activities were carried out in accordance with ICH GCP Guidelines and Declaration of Helsinki 1989.
Procedures
Prior to the start of the study, a familiarization session was conducted with the motion challenge and SC assessment. On another study session, the volunteers undertook the various CNS assessments on four repeated occasions to remove any training effects [13] .
On the study days involving the motion challenge, the study medication was administered 90 min prior to initiation of the challenge. On the cognitive function assessment days, the tasks were administered on arrival, prior to study treatment administration, and then again at 1.5, 3 and 4.5 h after dosing.
Motion challenge
Motion sickness was elicited by cross-coupled stimulation on a turntable, with subjects blindfolded (Figure S1 -S3). The rotational velocity was incremented by 2°s À1 every 30 s, and a sequence of eight head movements of 45°were completed every 30 s [14] . Motion was stopped at moderate nausea, or 40 min, whichever occurred sooner. Subjects rated their degree of motion sickness on the following scale: 1 = no symptoms; 2 = any symptoms however slight; 3 = mild symptoms, e.g. stomach awareness but no nausea; 4 = mild nausea; 5 = mild to moderate nausea; 6 = moderate nausea but can continue; 7 = moderate nausea, want to stop motion challenge [15] . At the end of motion, a sickness symptom checklist was administered for: dizziness, bodily warmth, headache, sweating, stomach awareness, increased salivation, funny taste in mouth, dry mouth and nausea (symptom scoring: nil = 0, mild = 1, moderate = 2, severe = 3).
Skin conductance
The skin conductance (SC) method employed was similar to that developed by Golding [14] . SC was recorded from 1st and 2nd finger palmar sites of the non-dominant hand, and from the left and right sides of the forehead close to the hairline approximately 2-4 cm above the eyebrows (supra-orbital ridge). Ag/AgCl electrodes were attached with double-sided self-adhesive stickers. Total effective electrical skin contact area was 0.32 cm 2 for the two finger electrodes and 0.32 cm 2 for the two forehead electrodes. The electrolyte used was 0.05 M NaCl, in the range found in human sweat [16] . The electrolyte jelly was made up with carboxymethylcellulose as the gel agent: NaCl 0.3 g plus low substitution carboxymethylcellulose 5 g (BDH Ltd) plus water to 100 g total [17] . SC was measured using two constant current (10 μA) mainsisolated devices built in the laboratory. Output was recorded in terms of DC-coupled (tonic) SC level (SCL) and as the amplified AC-coupled high pass signal (phasic) SC responses (SCRs) (corner frequency 0.14 Hz). Following 12-bit A/D conversion at 5 Hz with anti-aliasing low pass filter above 2 Hz, the SCL and SCR signals were displayed online and stored on hard disk with automatic diskette back-up. SCR, expressed as μmho root mean square (RMS), was subsequently analysed in the frequency band 0.005-0.48 Hz.
Tests of CNS function
The volunteers were trained on the cognitive function assessments prior to the main study. Each volunteer completed all the procedures four times during this training. Subsequently, on each study day in which cognitive function was assessed, the volunteers performed the tests 1 h prior to dosing and at 1.5, 3.5 and 4.5 h afterwards. The cognitive function tests took approximately 25 min to complete. They were preceded by a mood and alertness questionnaire. This questionnaire comprised 16 100 mm visual analogue scales which were combined as recommended by Bond and Lader [18] to derive three factors: subjective alertness, subjective calmness and subjective contentment. The questionnaire has proven sensitive to a wide range of compounds [19] [20] [21] . On each testing session, parallel forms were administered, where appropriate (i.e. different lists of words, different sequences of digits and different random sequences in tasks where the order of stimuli is randomized). All tasks were computer controlled, the information being presented on high resolution monitors and then responses recorded via response modules containing two buttons, one marked "NO" and the other "YES" [22] [23] [24] [25] .
Statistical analysis
Following an initial scrutiny of the motion sickness data, checks were performed for appropriate symptom patterns and for significance of order effects. Internal consistency checks were performed on times to motion endpoint between practice and placebo sessions, and between individual symptom items. Analyses were carried out to examine the effects of systematic exclusions of subject/treatment combinations where no nausea was reported at endpoint, or where the symptom pattern was highly suspect -for example, nausea but no stomach awareness -that is, to exclude those data where motion was terminated at a nominal sickness rating of 7 but where the meaning of this rating was open to doubt. Two-minute blocks of SC data were extracted from the beginning of the motion challenge, i.e. well prior to the onset of initial symptoms of motion sickness, and 2-min blocks of SC data were taken at the end of the motion challenge, i.e. during the period of time of maximum motion sickness. The differences between the first and last 2 min block of each finger and head SC dataset were addressed as a time factor in this analysis. A preliminary analysis of variance (ANOVA) was performed on the log-transformed dataset to examine whether there was any significant run order effect. No such run order effect was found, and therefore the analysis proceeded to address the treatment and time effects. ANOVA was applied to partition the overall variation in the logtransformed dataset, according to time, treatment and the two-way interaction between them. Newman-Keuls tests were applied to assess the differences between the individual treatments for each SC channel. In addition to ANOVAs, non-parametric tests (Wilcoxon) were used as appropriate.
For the cognitive function data, the statistical analysis was performed as follows: all data was adjusted for the predosing scores on a study day to derive "difference from baseline scores".
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY [26] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [27] .
Results
Motion challenge
Visual scrutiny of times to sickness ratings revealed an appropriate pattern of symptoms. Therefore, an initial analysis of the data was made using ANOVAs and non-parametric (Wilcoxon) tests, which would be less sensitive to extreme responses than parametric analysis. Times to sickness rating 7 were significantly longer for hyoscine hydrobromide compared with placebo (P = 0.027, two-tailed Wilcoxon test), but darifenacin at either dose was not significantly different from placebo ( Figure 1 , Table 1, Table S2 ).
Data were identified for exclusion from the subsequent analysis by ANOVA by scrutinizing for treatment/subject combinations that were unusual in terms of the expected associations between nausea and stomach awareness for symptom scores at motion endpoint, or typically where low nausea was recorded at motion endpoint (Table S2 ). In the latter event, it was possible that a subject may have stopped for other reasons such as dizziness.
A series of ANOVAs used these systematic exclusions of subject/treatment combinations. The majority of hyoscine hydrobromide versus placebo comparisons were significant (21/32 comparisons at P < 0.05; 15/32 comparisons at P < 0.001), whereas none were significant for darifenacin (10 or 20 mg) versus placebo.
On average hyoscine hydrobromide 0.6 mg produced an increased motion tolerance over placebo of around 3 min, whereas darifenacin 10 or 20 mg produced an increased motion tolerance over placebo averaging around 1 min (Figure 1) .
Symptom scores at motion endpoint
ANOVA of symptom scores at motion endpoint revealed significant treatment effects on dry mouth, salivation and bodily warmth. Dry mouth was significantly higher for hyoscine hydrobromide (P < 0.05) and for darifenacin (10 mg P < 0.05, 20 mg P < 0.001) versus placebo. Salivation and bodily warmth were both significantly lower (P < 0.05) with darifenacin 20 mg versus placebo. Symptom scores at motion endpoint are presented in Figure 2 .
Figure 1
Mean times to sickness rating 7 "moderate nausea and wish to stop" (motion endpoint) for the three active treatments and placebo, repeated on n = 15 subjects completing all treatments. Motion sickness was elicited by cross-coupled stimulation on a turntable. The mean times shown are representative of the range of results produced by exclusions on the basis of statistical symptom pattern tests, or on the basis of contradictions between nominal sickness rating and recorded symptoms such as nausea and stomach awareness at motion endpoint. The majority of hyoscine hydrobromide (HBr) 0.6 mg versus placebo comparisons were significant (P < 0.05 to P < 0.001), whereas none were significant for darifenacin (10 or 20 mg) versus placebo 
Skin conductance
An example SC recording is shown in Figure 3 . Figure 4 presents example palmar phasic SC records for the four treatment conditions, prior to motion sickness. Figure 5 presents the mean SC activity for the initial 2-min sample pre-motion sickness and the final 2-min sample during motion sickness. For finger SC, the mean log signal power for the last 2-min block was larger, to a small but significant extent, than that for the first 2 min (F(1,15) = 4.922, P < 0.05). There was also a significant treatment effect (F(3,15) = 8.099, P < 0.01). All three drug treatments gave significantly lower mean log signal power than did placebo, but the three drug treatments were not significantly different one from another. The overall difference between 10 mg darifenacin and placebo, and
Figure 2
Mean symptom scores (0 = nil, 1 = mild, 2 = moderate, 3 = severe) are shown at the motion endpoint of sickness rating 7, for n = 15 subjects completing all treatments. The most consistent effect was that darifenacin and hyoscine hydrobromide (HBr) increased subjective dry mouth
Figure 3
Skin conductance recordings at forehead and finger palmar sites during motion sickness challenge show finger palmar site being active throughout the test, showing non-specific response, whereas the forehead site is showing rapid increase at the onset of moderate nausea, as reflected in the increase in sickness rating, at approximately 13 min
Figure 4
Palmar finger skin conductance activity plots for one subject over the four treatments, prior to the onset of motion sickness. All traces are of 4 min duration starting at the beginning of the motion challenge, time zero. Note that oral hyoscine hydrobromide (HBr) 0.6 mg and oral darifenacin 10 mg and 20 mg, all reduce skin conductance activity by comparison with placebo. The effect was most marked for the high darifenacin dose
Figure 5
Mean phasic skin conductance activity, at the palmar finger and forehead sites, is plotted for the four treatment conditions. The mean phasic skin conductance activity is based on 2-min samples at the beginning of the motion challenge prior to motion sickness, and 2-min samples at the end of the motion challenge during maximum motion sickness. Darifenacin and hyoscine hydrobromide (HBr) significantly reduced phasic skin conductance activity compared with placebo (for example, see Figure 3 ). At the forehead recording site, the rise in skin conductance activity over time represented motion sickness-induced sweating (for example, see forehead signal in Figure 4) Effects of selective muscarinic receptor antagonist (darifenacin) on motion sickness between 0.6 mg hyoscine hydrobromide and placebo were both significant at P < 0.05. The overall difference between placebo and 20 mg darifenacin was significant at P < 0.01. Specific comparisons of each drug treatment versus placebo were performed for equivalent time periods, in order to further isolate effects. These are shown in Figure 5 .
For forehead SC, the mean log signal power for the last 2-min block was significantly greater than that for the first 2 min (F(1,33) = 17.999, P < 0.001). The treatment effect was marginal (F(3,15) = 2.951, P = 0.06). The overall difference between placebo and 20 mg darifenacin showed a significantly lower mean log power for darifenacin, at P < 0.05. Specific comparisons of each drug treatment versus placebo were performed for equivalent time periods, in order to further isolate effects. These are shown in Figure 5 .
Cognitive function testing
Oral hyoscine hydrobromide significantly reduced the accuracy of choice reaction time performance and increased body sway. A number of trends for impairment were detected, particularly at 4.5 h post-dosing where vigilance accuracy was decreased, tracking error increased and performance on the digit symbol substitution tests and critical flicker fusion tests impaired. When hyoscine hydrobromide was compared directly to darifenacin, performance with hyoscine hydrobromide was consistently found to be inferior to that with one or both darifenacin doses. At 1.5 h post dosing, significant impairments with hyoscine hydrobromide were seen on simple reaction time, body sway, vigilance accuracy, DSST performance, CCF tracking, working memory sensitivity and subjective alertness. The only clearly negative effect of darifenacin was for both doses to significantly increase body sway 4.5 h post-dosing (Table S1 ).
Discussion
The aim of this experiment was to investigate the effects of darifenacin and hyoscine hydrobromide on motion sickness, sweating and psychomotor performance. At the dose used, hyoscine hydrobromide produced a significantly increased motion tolerance over placebo of around 3 min, whereas darifenacin 10 or 20 mg non-significantly increased motion tolerance over placebo by around 1 min. To place these motion sickness protection values in context, a previous trial [8] using comparable methods but different subjects [28] demonstrated that hyoscine hydrobromide 0.6 mg gave a significantly increased tolerance over placebo of 2.9 min. Thus, the results for hyoscine hydrobromide in the present trial (3 min) were consistent with what might be expected from other evidence using this method.
Any putative anti-motion sickness effect for darifenacin in the dose range here would be small by comparison to hyoscine hydrobromide 0.6 mg. Given the negative evidence for the role of M1 or M2 receptors [29] and positive evidence (zamifenacin) for a role for M3/M5 receptors in mediating anti-motion sickness actions [8], the negative results of this experiment for M3 point to a more important role for the M5 receptor. A role for the M4 autoreceptor in motion sickness is also possible.
Darifenacin significantly reduced ongoing SC activity at the fingers before motion sickness, as did hyoscine hydrobromide. The darifenacin-induced reduction of SC activity, across the dose range employed, was similar in magnitude to that produced by hyoscine hydrobromide. Although the higher dose of darifenacin appeared to give the larger effect, a dose-response effect between 10 mg and 20 mg of darifenacin could not be demonstrated at a level of statistical significance. A broadly similar pattern of effects was observed at the finger sites during motion sickness.
Forehead sweating at baseline was minimal, which unsurprisingly was not significantly further reduced by the drugs. SC activity increased significantly during motion sickness, particularly at the forehead recording site, a finding consistent with previous work [14] . Darifenacin and hyoscine hydrobromide significantly reduced this activity. A dose-response effect between 10 mg and 20 mg of darifenacin could not be demonstrated at a level of statistical significance, although the higher dose of darifenacin appeared to give the larger effect compared with placebo.
The reduction of forehead sweating during motion sickness observed with darifenacin or hyoscine hydrobromide was probably due to a direct drug action on sweating. The possibility of drug action on SC activity via CNS effects cannot be ruled out entirely since the drugs were given systemically. The muscarinic postganglionic innervation of the sweat gland is thought to be of the M3 type [30] , suggesting that the action on SC activity of either drug is by virtue of their actions at such receptors.
Subjective symptoms of dry mouth were significantly higher for hyoscine hydrobromide and for darifenacin versus placebo. Salivation and bodily warmth were both significantly lower with darifenacin 20 mg versus placebo. Such effects are consistent with the well-known profile of action of anti-muscarinics on secretory glands and are probably occurring at the M3 receptor [30] . This pattern of response would also be consistent with the significant sweating reduction noted above for hyoscine hydrobromide and darifenacin on the SC measures.
When hyoscine hydrobromide was compared directly to darifenacin, performance with hyoscine hydrobromide was consistently found to be inferior to that with one or both of the darifenacin doses. At 1.5 h post dosing, significant impairments with hyoscine hydrobromide were seen on simple reaction time, body sway, vigilance accuracy, DSST performance and subjective alertness. At 4.5 h, similar significant effects were seen on vigilance accuracy, DSST performance, CFF tracking, working memory sensitivity and subjective alertness.
Darifenacin was largely free of impairing effects on cognition; in fact, performance appeared to be improved by the drug. Both doses significantly improved simple reaction time and the low dose significantly improved working memory sensitivity, subjective alertness and subjective contentment. The high dose showed improved choice reaction time while the low dose showed a similar trend for improving vigilance reaction time. The only clearly negative effect of darifenacin was for both doses to significantly increase body sway 4.5 h post-dosing. The absence of an increase in tracking error with darifenacin strongly suggests that this was not an effect on coordination and thus the basis for this effect on postural stability is unclear. The magnitude of the effect is in the region of that produced by two to three units of alcohol and thus is clearly not a marked effect. These findings consistently demonstrate that subjects will be better off in terms of their ability to concentrate and conduct skilled activities when taking darifenacin than when taking hyoscine hydrobromide at the doses used in this study.
Overall, the present study has demonstrated that when the volunteers received hyoscine hydrobromide, their general ability to maintain attention and concentrate was inferior to that when they were given darifenacin. This is in part due to the impairments produced by hyoscine hydrobromide but exaggerated in some cases by unexpected improvements seen with darifenacin. Nonetheless, the outcome is that volunteers would clearly be in a better position to drive and conduct activities requiring high levels of concentration and coordination when taking darifenacin than while taking hyoscine hydrobromide.
Hyoscine hydrobromide produced significant decrements in psychomotor performance, which were similar to previous published data [4] . Darifenacin produced little or no impairment at either dose or even an enhanced effect on certain parameters, suggesting that such impairments produced by hyoscine hydrobromide are not mediated by M3 receptors.
Muscarinic receptors expressed in the brain modulate a multitude of signalling pathways involved in critical functions including attention, memory and learning. Quantitative analysis studies have identified the five subtypes with varying expression levels throughout the brain. M1, M2 and M4 are the dominant subtypes, while M3 and M5 are found at lower levels [31] .
M1 receptors are of particular interest in the cortical areas and the hippocampus [32] as it has been shown that their inhibition leads to impaired spatial memory [31] . Molecular manipulations of the m1 gene have been shown to cause cognitive deficits [33] , whereas the administration of known agonists of the M1 receptor subtype in human subjects with Alzheimer's disease and schizophrenia improved memory and learning [34, 35] . These findings indicate that M1 receptor antagonism causes adverse reactions in the CNS [36] .
Delivery of drugs to the CNS depends on molecular characteristics; these include molecular size, polarity and lipophilicity (Table S3) [7, 8, [37] [38] [39] [40] . The physicochemical properties of oxybutynin and hyoscine hydrobromide grant these molecules high propensity to penetrate the bloodbrain barrier freely, thus high concentrations can reach the central M1 receptors [41] .
The affinity of anti-muscarinics for specific receptors is an important factor contributing to CNS effects. Oxybutynin has been shown to have similar selectivity for M1 and M3 receptors (pK i 8.7 and 8.9, respectively) and is considered non-selective [32] . Short-term studies have demonstrated impairment of cognitive function after oxybutynin therapy [42] . A recent observational study has shown that chronic usage of oxybutynin in patients with UUI is associated with a significant increase in the incidence of dementia [43] . The positive cognitive function data shown in this study should be confirmed in long-term studies in patients with UUI treated with darifenacin. It would seem axiomatic to avoid chronic usage of anti-muscarinic agents that result in adverse effects on cognitive function which may not be reversible and lead to dementia.
We conclude that the muscarinic M3 receptor is unlikely to be the most important receptor mediating the anti-motion sickness actions of hyoscine hydrobromide. This result, in conjunction with other data, indicates a more important role for the M5 receptor in motion sickness. In addition, this study suggests that selective antagonism of the M3 receptor does not produce a deleterious effect on cognitive function. This observation may be important when considering selection of a suitable antimuscarinic agent for long-term treatment of chronic conditions such as UUI.
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